Printer Friendly

Vysis Grants License to bioMerieux, Inc. Under Its Collins Patent.

Technology Improves Sensitivity of DNA Probe Technology Using Amplification

DOWNERS GROVE, Ill., July 10 /PRNewswire/ --

Vysis, Inc. (Nasdaq: VYSI), a developer and marketer of DNA-based clinical products providing information for genomic disease management, announced today that it has granted a nonexclusive license to bioMerieux, Inc. under its U.S. Patent No. 5,750,338 (the Collins patent) and related patents. The Collins patent relates to nucleic acid diagnostic methods utilizing target capture and in vitro amplification. It is currently licensed by Gen-Probe Incorporated and is the object of invalidity and non-infringement litigation initiated by Gen-Probe.

"The license granted to bioMerieux is royalty-bearing and consistent with the other licenses Vysis has granted under the Collins patent," said Norval B. Galloway, Vysis' Patent Counsel. Specific terms of the license were not disclosed.

Vysis, Inc. of Downers Grove, IL, is a genomic disease management company that develops, commercializes and markets DNA-based clinical products providing information critical to the evaluation and management of cancer, prenatal disorders and other genetic diseases. The company has direct sales operations in the United States and Europe, a marketing partnership in Japan with Fujisawa Pharmaceutical Co., and a worldwide distribution network.

The statements made in this release about future transactions and sale of Vysis securities are "forward-looking" statements and are subject to risks and uncertainties inherent in the company's business. These risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements, include: the market acceptance of the company's clinical products; the extent to which the clinicians or laboratories performing the procedures with the company's products are able to obtain third-party reimbursement; the ability of the company to successfully market and sell its clinical products, other products and equipment; competition; compliance by the company with regulatory requirements and the timely receipt of necessary governmental approvals; the company's ability to manufacture products in sufficient quantities; the company's ability to maintain intellectual property protection for its proprietary products, to defend its existing intellectual property rights from challenges by third parties, and to avoid infringing intellectual property rights of third parties; and the company's cost control efforts. In addition, a detailed discussion of risks and uncertainties may be found in the company's periodic filings with the Securities and Exchange Commission. Vysis disclaims any intent or obligation to update these forward-looking statements.

To receive Vysis, Inc.'s latest news release and other corporate documents, free of charge via fax, simply dial 1-800-PRO-INFO. Use company ticker VYSI.

COPYRIGHT 2001 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:1USA
Date:Jul 10, 2001
Previous Article:Pfizer Invites Public to Listen to Webcast Of July 17 Conference Call With Analysts.
Next Article:Bull Run Corporation Subsidiary Selected By CBS Sports to Administer NCAA Marketing Programs.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters